A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01209962|
Recruitment Status : Completed
First Posted : September 27, 2010
Last Update Posted : July 5, 2017
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response|
|Study Start Date :||May 2008|
|Actual Primary Completion Date :||May 26, 2015|
|Actual Study Completion Date :||May 26, 2015|
The majority of recruited patients will be treated on protocol HUM00004531 "A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer".
- Diffusion MRI [ Time Frame: 5 years ]The goal is to develop a functional imaging method that would be a better predictor of pathological response than the current CT standard. Diffusion MRI has the potential to measure early cellular changes that occur in response to successful therapies, such as chemoradiation, and has been demonstrated to be an early predictor not only of therapeutic response, but also of overall survival for other malignancies.
- Apparent Diffusion Coefficient (ADC) [ Time Frame: 5 years ]Demonstrate that the distribution of Apparent Diffusion Coefficient in pancreatic tumors, as measured by diffusion MRI, changes in response to neoadjuvant chemoradiotherapy, and characterize the differences in the distributions between histopathologic responders and non-responders.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01209962
|United States, Michigan|
|University of Michigan Cancer Center|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Kyle Cuneo, MD||University of Michigan Cancer Center|